Fr486 ORAL ADMINISTRATION OF THE MELANOCORTIN-1 RECEPTOR AGONIST PL8177 IN A RAT MODEL OF COLITIS

Hyperuricemia (HUA) is a metabolic disorder of purine metabolism which leads to the increase of serum uric acid. Tongfeng Lian granule (TFLA) is a clinical empirical traditional herb prescription in China, is biobased natural product material. To study its regulatory mechanism on uric acid transporter in rats with HUA, the rat model of hyperuricemic was established by oral administration of potassium oxazinate (1.5 g/kg) and adenine (0.05 g/kg). The related indexes were detected to evaluate the uric Acid Transporter after treat with TFLA. In the results, compared with model group, the high dose TFLA can reduce the levels of Related serum biochemical indexes (*P < 0.05, **P < 0.01). TFLA could reduce the levels of URAT1, GLUT9 and increase the expression of OAT3 in kidney. In conclusion, TFLA can effectively inhibit the level of serum uric acid with hyperuricemia rats, and the possible mechanism related to TFLA inhibiting the reabsorption of uric acid by URAT1 and GLUT9, promoting the secretion of OAT3 and uric acid into urine.

Download Full-text

Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia

Pharmacological Reports ◽

10.1016/j.pharep.2017.05.002 ◽

2017 ◽

Vol 69 (5) ◽

pp. 1113-1119 ◽

Cited By ~ 7

Author(s):

Beata Nowak ◽

Agnieszka Matuszewska ◽

Anna Nikodem ◽

Jarosław Filipiak ◽

Marcin Landwójtowicz ◽

...

Keyword(s):

Bone Loss ◽

Oral Administration ◽

Rat Model

Download Full-text

Cannabinoid Receptor Agonist WIN55, 212-2 Adjusts Lipid Metabolism in a Rat Model of Cardiac Arrest

Therapeutic Hypothermia and Temperature Management ◽

10.1089/ther.2019.0038 ◽

2020 ◽

Vol 10 (4) ◽

pp. 192-203 ◽

Cited By ~ 1

Author(s):

Yan Xiao ◽

Daniel Contaifer ◽

Weiping Huang ◽

Jin Yang ◽

Zhangle Hu ◽

...

Keyword(s):

Cardiac Arrest ◽

Lipid Metabolism ◽

Rat Model ◽

Receptor Agonist ◽

Cannabinoid Receptor

Download Full-text

Melanogenic effect of dersimelagon (MT‐7117), a novel oral melanocortin 1 receptor agonist

Skin Health and Disease ◽

10.1002/ski2.78 ◽

2021 ◽

Author(s):

T. Suzuki ◽

Y. Kawano ◽

A. Matsumoto ◽

M. Kondo ◽

K. Funayama ◽

...

Keyword(s):

Receptor Agonist ◽

Melanocortin 1 Receptor

Download Full-text

The contribution of muscarinic-receptor-mediated responses to epineurial vascular diameter at the sciatic nerve

Canadian Journal of Physiology and Pharmacology ◽

10.1139/cjpp-2018-0166 ◽

2018 ◽

Vol 96 (8) ◽

pp. 855-858

Author(s):

Chelsa Killey ◽

Shane Cleary ◽

Julie Orr ◽

Jefferson C. Frisbee ◽

Dwayne Jackson ◽

...

Keyword(s):

Mean Arterial Pressure ◽

Sciatic Nerve ◽

Arterial Pressure ◽

Muscarinic Receptor ◽

Topical Application ◽

Rat Model ◽

Receptor Agonist ◽

Vessel Diameter ◽

Anaesthetized Rat ◽

Baseline Diameter

This study used an anaesthetized rat model to directly observe changes in diameter of the vessels supplying the sciatic nerve in response to acetylcholine (10−4 M), a muscarinic receptor agonist, and atropine (10−5 M), a muscarinic receptor antagonist. Topical application of acetylcholine resulted in increases in vessel diameter (baseline: 22.0 ± 2.5 μm, acetylcholine: 28.8 ± 3.3 μm), while topical application of atropine resulted in a decrease in diameter (baseline: 26.6 ± 3.2 μm, atropine: 15.5 ± 3.6 μm) of the epineurial vessels. Mean arterial pressure was not affected by either acetylcholine (baseline: 103.8 ± 1.8 mm Hg, acetylcholine: 102.8 ± 3.2 mm Hg) or atropine (baseline: 104.0 ± 1.9 mm Hg, atropine: 105.2 ± 2.2 mm Hg). These data suggest that muscarinic-receptor-mediated responses can affect the diameter of the epineurial vessels at the sciatic nerve. In addition, muscarinic-receptor-mediated responses appear to contribute to baseline diameter of epineurial vessels at the sciatic nerve.

Download Full-text